Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Cytokinetics - Stock

Cytokinetics Stock

CYTK
US23282W6057
A1W1KK

Price

55.51
Today +/-
+0
Today %
+0 %
P

Cytokinetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cytokinetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cytokinetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cytokinetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cytokinetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cytokinetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cytokinetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cytokinetics’s growth potential.

Cytokinetics Revenue, EBIT and net profit per share

DateCytokinetics RevenueCytokinetics EBITCytokinetics Net Income
2029e2.3 B undefined0 undefined833.33 M undefined
2028e1.64 B undefined566.57 M undefined547.82 M undefined
2027e979.7 M undefined93.65 M undefined177.17 M undefined
2026e372.92 M undefined-256.18 M undefined-296.91 M undefined
2025e84.29 M undefined-461.75 M undefined-514.72 M undefined
2024e14.67 M undefined-481.72 M undefined-535.46 M undefined
20237.53 M undefined-496.21 M undefined-526.24 M undefined
202294.6 M undefined-324.2 M undefined-389 M undefined
202170.4 M undefined-186.3 M undefined-215.3 M undefined
202055.8 M undefined-93.9 M undefined-127.3 M undefined
201926.9 M undefined-98.9 M undefined-121.7 M undefined
201831.5 M undefined-88.9 M undefined-106.3 M undefined
201713.4 M undefined-113.4 M undefined-127.8 M undefined
2016106.4 M undefined18.7 M undefined16.5 M undefined
201528.7 M undefined-37.4 M undefined-37.5 M undefined
201446.9 M undefined-14.8 M undefined-14.6 M undefined
201330.6 M undefined-33.9 M undefined-33.7 M undefined
20127.6 M undefined-40.6 M undefined-41.7 M undefined
20114 M undefined-46.8 M undefined-50.7 M undefined
20102.6 M undefined-49.6 M undefined-49.3 M undefined
200981.5 M undefined26.1 M undefined24.5 M undefined
200812.4 M undefined-56.6 M undefined-56.4 M undefined
200713.6 M undefined-56.5 M undefined-48.9 M undefined
20063.1 M undefined-61.3 M undefined-57.1 M undefined
20058.9 M undefined-44.6 M undefined-42.3 M undefined
200413.4 M undefined-38.4 M undefined-37.2 M undefined

Cytokinetics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00.010.010.010.010.0100.010.010.08000.010.030.050.030.110.010.030.030.060.070.090.010.010.080.370.981.642.3
--37.50-9.0930.00-38.46-62.50333.33-7.69575.00-97.53100.0075.00328.5753.33-39.13278.57-87.74138.46-16.13111.5427.2734.29-92.55100.00500.00342.86163.1767.1140.65
------------------------------
000000000000000000000000000000
-13-18-24-32-38-44-61-56-5626-49-46-40-33-14-3718-113-88-98-93-186-324-496-481-461-256935660
--225.00-218.18-320.00-292.31-550.00-2,033.33-430.77-466.6732.10-2,450.00-1,150.00-571.43-110.00-30.43-132.1416.98-869.23-283.87-376.92-169.09-265.71-344.68-7,085.71-3,435.71-548.81-68.829.5034.60-
-13-15-23-32-37-42-57-48-5624-49-50-41-33-14-3716-127-106-121-127-215-389-526-535-514-296177547833
-15.3853.3339.1315.6313.5135.71-15.7916.67-142.86-304.172.04-18.00-19.51-57.58164.29-143.24-893.75-16.5414.154.9669.2980.9335.221.71-3.93-42.41-159.80209.0452.29
4.94.94.933.34.86.17.98.29.710.711.818.127.335.738.842.649.454.457.664.576.989.896.52000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Cytokinetics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cytokinetics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cytokinetics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cytokinetics's financial health and stability.

Assets

Cytokinetics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cytokinetics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cytokinetics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cytokinetics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-13-15-23-32-37-42-57-48-5624-49-47-40-33-14-3716-127-106-121-127-215-388-526
0123332222110000011112511
000000000000000000000000
011-1-2-2-1237-13-24-1-2222-3437120-22-3878-243
000111451111867769143236446488156168
00000000000000001224991510
000000000000000000000000
-11-1-21-30-34-39-47-3-618-44-45-33-7-44436-101-101-908-142-299-414
-2-3-6-3-1-1-5-2000000-10-1-20-2-11-48-11-1
-25-2322-15-6534-1345-9-533425-28-1-416-52-655-74-196-147-262239
-22-1929-12-6435-848-9-523425-280-216-50-626-72-185-98-250240
000000000000000000000000
034004187-415212001415191350048449
5513040101168270130205514489113433723131917182
551744010258634-328221581448231622513159234319516221
00000000000000000900-132014-10
000000000000000000000000
18-85-5202577-74-16-81-35044158-82-54629-4546
-13.56-5.59-28.4-33.75-35.43-40.95-52.54-5.57-61.997.87-45.32-46.04-33.57-8.26-45.944.3235.38-104.64-102.11-93.53-2.11-191.39-310.86-415.75
000000000000000000000000

Cytokinetics stock margins

The Cytokinetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cytokinetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cytokinetics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cytokinetics's sales revenue. A higher gross margin percentage indicates that the Cytokinetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cytokinetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cytokinetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cytokinetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cytokinetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cytokinetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cytokinetics Margin History

Cytokinetics Gross marginCytokinetics Profit marginCytokinetics EBIT marginCytokinetics Profit margin
2029e0 %0 %36.22 %
2028e0 %34.61 %33.46 %
2027e0 %9.56 %18.08 %
2026e0 %-68.69 %-79.62 %
2025e0 %-547.83 %-610.68 %
2024e0 %-3,284.41 %-3,650.8 %
20230 %-6,589.71 %-6,988.63 %
20220 %-342.71 %-411.21 %
20210 %-264.63 %-305.82 %
20200 %-168.28 %-228.14 %
20190 %-367.66 %-452.42 %
20180 %-282.22 %-337.46 %
20170 %-846.27 %-953.73 %
20160 %17.58 %15.51 %
20150 %-130.31 %-130.66 %
20140 %-31.56 %-31.13 %
20130 %-110.78 %-110.13 %
20120 %-534.21 %-548.68 %
20110 %-1,170 %-1,267.5 %
20100 %-1,907.69 %-1,896.15 %
20090 %32.02 %30.06 %
20080 %-456.45 %-454.84 %
20070 %-415.44 %-359.56 %
20060 %-1,977.42 %-1,841.94 %
20050 %-501.12 %-475.28 %
20040 %-286.57 %-277.61 %

Cytokinetics Stock Sales Revenue, EBIT, Earnings per Share

The Cytokinetics earnings per share therefore indicates how much revenue Cytokinetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cytokinetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cytokinetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cytokinetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cytokinetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cytokinetics Revenue, EBIT and net profit per share

DateCytokinetics Sales per ShareCytokinetics EBIT per shareCytokinetics Earnings per Share
2029e19.83 undefined0 undefined7.18 undefined
2028e14.11 undefined0 undefined4.72 undefined
2027e8.44 undefined0 undefined1.53 undefined
2026e3.21 undefined0 undefined-2.56 undefined
2025e0.73 undefined0 undefined-4.44 undefined
2024e0.13 undefined0 undefined-4.61 undefined
20230.08 undefined-5.14 undefined-5.45 undefined
20221.05 undefined-3.61 undefined-4.33 undefined
20210.92 undefined-2.42 undefined-2.8 undefined
20200.87 undefined-1.46 undefined-1.97 undefined
20190.47 undefined-1.72 undefined-2.11 undefined
20180.58 undefined-1.63 undefined-1.95 undefined
20170.27 undefined-2.3 undefined-2.59 undefined
20162.5 undefined0.44 undefined0.39 undefined
20150.74 undefined-0.96 undefined-0.97 undefined
20141.31 undefined-0.41 undefined-0.41 undefined
20131.12 undefined-1.24 undefined-1.23 undefined
20120.42 undefined-2.24 undefined-2.3 undefined
20110.34 undefined-3.97 undefined-4.3 undefined
20100.24 undefined-4.64 undefined-4.61 undefined
20098.4 undefined2.69 undefined2.53 undefined
20081.51 undefined-6.9 undefined-6.88 undefined
20071.72 undefined-7.15 undefined-6.19 undefined
20060.51 undefined-10.05 undefined-9.36 undefined
20051.85 undefined-9.29 undefined-8.81 undefined
20044.06 undefined-11.64 undefined-11.27 undefined

Cytokinetics business model

Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.com.

Cytokinetics SWOT Analysis

Strengths

1. Innovative Research and Development: Cytokinetics Inc is known for its strong commitment to developing breakthrough therapies for patients with severe diseases.

2. Robust Pipeline: The company has a diverse and promising pipeline of potential drug candidates, targeting various indications including cardiovascular and neuromuscular diseases.

3. Strategic Partnerships: Cytokinetics has formed strategic collaborations with renowned pharmaceutical companies, enhancing its capabilities and resources in advancing drug development.

Weaknesses

1. Limited Product Portfolio: The company heavily relies on the success of its drug candidates, with a limited number of approved products currently available.

2. Dependency on Key Partnerships: Cytokinetics relies on collaborations with partners for funding, expertise, and market access, which introduces a level of dependency and risk.

3. Regulatory Challenges: Like any pharmaceutical company, Cytokinetics faces regulatory hurdles and uncertainty, which can significantly impact the approval and market viability of its drug candidates.

Opportunities

1. Growing Demand for Innovative Therapies: The increasing prevalence of cardiovascular and neuromuscular diseases presents an immense opportunity for Cytokinetics to address unmet medical needs with its R&D efforts.

2. Expansion into New Geographies: The company can explore new markets and expand its global footprint, potentially reaching a larger patient population and generating additional revenue streams.

3. Advancements in Technology: Emerging technologies like gene therapy and precision medicine provide opportunities for Cytokinetics to leverage scientific breakthroughs and develop novel treatment solutions.

Threats

1. Intense Market Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies working on similar therapies, posing a threat to Cytokinetics' market share.

2. Clinical Trial Setbacks: The failure of clinical trials or unexpected safety concerns can result in setbacks and delays, impacting both the company's reputation and financial performance.

3. Pricing and Reimbursement Pressures: Cytokinetics may face challenges in pricing its products competitively and navigating reimbursement processes, which can affect market penetration and profitability.

Cytokinetics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Cytokinetics shares outstanding

The number of shares was Cytokinetics in 2023 — This indicates how many shares 96.524 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cytokinetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cytokinetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cytokinetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cytokinetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cytokinetics Stock splits

In Cytokinetics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Cytokinetics.

Cytokinetics Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-1.16 -1.33  (-14.18 %)2024 Q1
12/31/2023-0.99 -1.38  (-39.39 %)2023 Q4
9/30/2023-0.76 -1.35  (-78.29 %)2023 Q3
6/30/2023-1.17 -1.34  (-14.64 %)2023 Q2
3/31/2023-1.22 -1.38  (-12.82 %)2023 Q1
12/31/2022-1.23 -1.45  (-17.89 %)2022 Q4
9/30/2022-1.19 -1.52  (-27.35 %)2022 Q3
6/30/2022-1.04 -0.23  (77.91 %)2022 Q2
3/31/2022-0.96 -1.02  (-5.96 %)2022 Q1
12/31/2021-0.86 -0.36  (57.99 %)2021 Q4
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Cytokinetics stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

62

Environment

Scope 1 - Direct Emissions
670
Scope 2 - Indirect emissions from purchased energy
830
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
1,500
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees8
Percentage of women in management—
Percentage of Asian employees38
Share of Asian management21
Percentage of Hispanic/Latino employees5
Hispano/Latino Management share—
Percentage of Black employees5
Black Management Share—
Percentage of white employees49
White Management Share76
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cytokinetics Stock Shareholders

%
Name
Stocks
Change
Date
9.99 % Fidelity Management & Research Company LLC11,598,8391,121,52812/31/2023
9.48 % The Vanguard Group, Inc.10,997,974273,56512/31/2023
5.59 % Wellington Management Company, LLP6,488,500-1,497,85612/31/2023
5.08 % State Street Global Advisors (US)5,893,358618,87212/31/2023
2.75 % T. Rowe Price Associates, Inc.3,192,7992,233,45012/31/2023
2.21 % Janus Henderson Investors2,568,40575,07912/31/2023
2.18 % RTW Investments L.P.2,525,080-49,11812/31/2023
12.80 % BlackRock Institutional Trust Company, N.A.14,854,640661,99112/31/2023
1.92 % T. Rowe Price Investment Management, Inc.2,229,485413,29912/31/2023
1.81 % Boxer Capital, L.L.C.2,100,000012/31/2023
1
2
3
4
5
...
10

Cytokinetics Executives and Management Board

Mr. Robert Blum59
Cytokinetics President, Chief Executive Officer, Director (since 1998)
Compensation 8.55 M
Dr. Fady Malik58
Cytokinetics Executive Vice President - Research and Development
Compensation 3.54 M
Mr. Ching Jaw60
Cytokinetics Chief Financial Officer, Senior Vice President
Compensation 2.62 M
Mr. Andrew Callos54
Cytokinetics Executive Vice President, Chief Commercial Officer
Compensation 2.55 M
Dr. Robert Harrington62
Cytokinetics Independent Director
Compensation 1.39 M
1
2
3

Cytokinetics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Royalty Pharma A - Stock
Royalty Pharma A
SupplierCustomer0,17-0,410,390,24-0,32-
Kilroy Realty - Stock
Kilroy Realty
SupplierCustomer-0,63-0,02-0,020,160,020,61
Amgen - Stock
Amgen
SupplierCustomer-0,83-0,140,44-0,01-0,41-0,40
Astellas Pharma - Stock
Astellas Pharma
SupplierCustomer-0,86-0,650,02-0,040,260,71
1

Cytokinetics stock: Frequently Asked Questions

What values and corporate philosophy does Cytokinetics represent?

Cytokinetics Inc is committed to improving the lives of patients by developing innovative therapies in the field of muscle biology. The company's core values include integrity, collaboration, and dedication to scientific excellence. Cytokinetics is driven by a corporate philosophy that emphasizes scientific rigor, patient-centricity, and a strong commitment to advancing medical knowledge. By working closely with key stakeholders, including healthcare professionals and patients, Cytokinetics aims to address unmet medical needs and make a positive impact on global healthcare. With its cutting-edge research and development efforts, Cytokinetics Inc strives to bring new treatment options to patients suffering from serious diseases and disorders affecting muscle function.

In which countries and regions is Cytokinetics primarily present?

Cytokinetics Inc is primarily present in the United States.

What significant milestones has the company Cytokinetics achieved?

Cytokinetics Inc has achieved significant milestones in its journey. One notable achievement is the development of omecamtiv mecarbil, a potential treatment for heart failure. The company has successfully completed various clinical trials, demonstrating promising results in improving cardiac function. Additionally, Cytokinetics Inc has advanced its research in muscle biology and therapeutics, leading to collaborations with renowned pharmaceutical companies and medical institutions. Furthermore, the company's continuous dedication to innovation and scientific excellence has resulted in numerous patents and publications. These milestones highlight Cytokinetics Inc's commitment to delivering innovative solutions and advancing the field of cardiac and skeletal muscle disorders.

What is the history and background of the company Cytokinetics?

Cytokinetics Inc is a renowned biopharmaceutical company specializing in the discovery and development of muscle biology-focused therapies. Established in 1997, the company has emerged as a leading player in the field, harnessing the power of sarcomere-directed drug candidates. Cytokinetics' innovative research and development aim to address diseases associated with muscle impairment and dysfunction. With a strong focus on cardiovascular and neuromuscular diseases, Cytokinetics Inc continues to progress its pipeline of potential treatments with the goal of improving patients' lives. Their commitment to scientific advancement and clinical collaboration places Cytokinetics Inc at the forefront of efforts to tackle serious medical conditions.

Who are the main competitors of Cytokinetics in the market?

The main competitors of Cytokinetics Inc in the market include pharmaceutical companies such as Amgen, Biogen, and Novartis. These companies also specialize in the development of cutting-edge therapies and drugs for various medical conditions. However, Cytokinetics Inc distinguishes itself through its novel approach to drug discovery, focusing on the field of muscle biology and developing potential treatments for diseases related to muscle dysfunction. With its innovative research and development strategies, Cytokinetics Inc aims to make significant contributions to the pharmaceutical industry and provide solutions that address unmet medical needs.

In which industries is Cytokinetics primarily active?

Cytokinetics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Cytokinetics?

The business model of Cytokinetics Inc is focused on the discovery and development of novel muscle activators as potential treatments for debilitating diseases. Cytokinetics utilizes its expertise in muscle biology to develop small molecule drug candidates that target muscle function and address diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By designing innovative therapies that aim to improve muscle performance, Cytokinetics aims to provide hope for patients suffering from these conditions and enhance their overall quality of life through its scientific research and drug development efforts.

What is the P/E ratio of Cytokinetics 2024?

The Cytokinetics P/E ratio is -10.01.

What is the P/S ratio of Cytokinetics 2024?

The Cytokinetics P/S ratio is 365.31.

What is the AlleAktien quality score of Cytokinetics?

The AlleAktien quality score for Cytokinetics is 5/10.

What is the revenue of Cytokinetics 2024?

The expected Cytokinetics revenue is 14.67 M USD.

How high is the profit of Cytokinetics 2024?

The expected Cytokinetics profit is -535.46 M USD.

What is the business model of Cytokinetics

Cytokinetics Inc. is a biopharmaceutical company based in South San Francisco, California. The company specializes in the development of novel therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. It utilizes expertise in cell biology, medical technology, and drug development to create precision medicine therapies tailored to clinical needs. The company has two main divisions: Cardiovascular and Neuromuscular. The Cardiovascular division focuses on developing therapeutics for diseases of the heart muscle and blood vessels. This includes heart muscle diseases such as heart failure and arrhythmias, as well as vascular diseases such as peripheral arterial disease and pulmonary arterial hypertension. The Neuromuscular division specializes in developing therapeutics for diseases of the skeletal muscle. This includes neuromuscular diseases such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy. Cytokinetics develops its therapeutics using an innovative class of drugs known as myosin activators. A myosin activator is a substance that activates the enzyme myosin, which is responsible for muscle contraction. By activating myosin, the muscle can work better and more effectively. One of Cytokinetics' key products is the investigational drug Omecamtiv Mercabil. It is an oral myosin activator for the treatment of heart failure. Omecamtiv's mechanism is aimed at increasing the contractile force of the heart muscle to improve blood flow and pumping. The continuous research and development of drugs like Omecamtiv Mercabil have the potential to usher in a new era of treatment for cardiovascular diseases. Cytokinetics also has a partnership with Astellas Pharma Inc. for the joint development of Reldesemtiv for spinal muscular atrophy, CK-274 for hypertrophic cardiomyopathy, and other neuromuscular indications. Collaborating with partners increases the likelihood of rapid and successful drug development and accelerates market introduction. Cytokinetics' business model is based on partnerships with other companies to accelerate the research and development of therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. By leveraging innovative technologies and platforms, and integrating data, human experience, and scientific intelligence, Cytokinetics brings novel medicines to market that could improve the quality of life for millions of patients worldwide.

What is the Cytokinetics dividend?

Cytokinetics pays a dividend of 0 USD distributed over payouts per year.

How often does Cytokinetics pay dividends?

The dividend cannot currently be calculated for Cytokinetics or the company does not pay out a dividend.

What is the Cytokinetics ISIN?

The ISIN of Cytokinetics is US23282W6057.

What is the Cytokinetics WKN?

The WKN of Cytokinetics is A1W1KK.

What is the Cytokinetics ticker?

The ticker of Cytokinetics is CYTK.

How much dividend does Cytokinetics pay?

Over the past 12 months, Cytokinetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cytokinetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cytokinetics?

The current dividend yield of Cytokinetics is .

When does Cytokinetics pay dividends?

Cytokinetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cytokinetics?

Cytokinetics paid dividends every year for the past 0 years.

What is the dividend of Cytokinetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cytokinetics located?

Cytokinetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cytokinetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cytokinetics from 7/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.

When did Cytokinetics pay the last dividend?

The last dividend was paid out on 7/6/2024.

What was the dividend of Cytokinetics in the year 2023?

In the year 2023, Cytokinetics distributed 0 USD as dividends.

In which currency does Cytokinetics pay out the dividend?

The dividends of Cytokinetics are distributed in USD.

Other fundamentals and analyses of Cytokinetics in the deep dive.

Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.